Effect	O
of	O
polyethylene	B-Chemical
glycol	I-Chemical
400	I-Chemical
on	O
adriamycin	B-Chemical
toxicity	B-Disease
in	O
mice	O
.	O

cTnT	O
found	O
in	O
rats	O
after	O
12	O
mg	O
/	O
kg	O
were	O
significantly	O
greater	O
than	O
that	O
found	O
after	O
7	O
.	O
5	O
mg	O
/	O
kg	O
DOX	B-Chemical
.	O

NRA0160	B-Chemical
and	O
clozapine	B-Chemical
significantly	O
induced	O
catalepsy	B-Disease
in	O
rats	O
,	O
although	O
their	O
effects	O
did	O
not	O
exceed	O
50	O
%	O
induction	O
even	O
at	O
the	O
highest	O
dose	O
given	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
investigated	O
whether	O
50	O
mg	O
/	O
kg	O
per	O
day	O
,	O
p	O
.	O
o	O
.	O
,	O
Ato	B-Chemical
could	O
prevent	O
endothelial	O
NO	B-Chemical
synthase	O
(	O
eNOS	O
)	O
downregulation	O
and	O
the	O
increase	O
in	O
O2	B-Chemical
-	I-Chemical
in	O
Sprague	O
-	O
Dawley	O
(	O
SD	O
)	O
rats	O
,	O
thereby	O
reducing	O
blood	O
pressure	O
.	O

Challenge	O
tests	O
with	O
AX	B-Chemical
were	O
performed	O
in	O
23	O
subjects	O
(	O
43	O
%	O
)	O
to	O
establish	O
the	O
diagnosis	O
of	O
immediate	O
allergic	B-Disease
reaction	I-Disease
to	O
AX	B-Chemical
,	O
and	O
in	O
15	O
cases	O
(	O
28	O
%	O
)	O
both	O
skin	O
test	O
and	O
RAST	O
for	O
AX	B-Chemical
were	O
negative	O
.	O

There	O
were	O
no	O
serious	O
clinical	O
side	O
effects	O
,	O
but	O
dose	O
reduction	O
was	O
required	O
in	O
two	O
patients	O
because	O
of	O
nausea	B-Disease
.	O

Pseudo	O
-	O
allergic	B-Disease
reactions	I-Disease
to	O
corticosteroids	B-Chemical
:	O
diagnosis	O
and	O
alternatives	O
.	O

The	O
patient	O
has	O
been	O
followed	O
for	O
six	O
years	O
and	O
has	O
required	O
pharmacologic	O
doses	O
of	O
pyridoxine	B-Chemical
to	O
control	O
her	O
behavior	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
and	O
compare	O
the	O
effects	O
of	O
coniine	B-Chemical
and	O
nicotine	B-Chemical
in	O
the	O
developing	O
chick	O
.	O

CONCLUSION	O
:	O
A	O
50	O
%	O
reduction	O
in	O
the	O
incidence	O
of	O
akathisia	B-Disease
when	O
prochlorperazine	B-Chemical
was	O
administered	O
by	O
means	O
of	O
15	O
-	O
minute	O
intravenous	O
infusion	O
versus	O
a	O
2	O
-	O
minute	O
intravenous	O
push	O
was	O
not	O
detected	O
.	O

A	O
40	O
-	O
year	O
-	O
old	O
man	O
with	O
leukemia	B-Disease
and	O
no	O
history	O
of	O
cardiac	B-Disease
disease	I-Disease
developed	O
recurrent	O
,	O
brief	O
episodes	O
of	O
apparent	O
sinus	B-Disease
arrest	I-Disease
while	O
receiving	O
continuous	O
-	O
infusion	O
cimetidine	B-Chemical
50	O
mg	O
/	O
hour	O
.	O

In	O
conclusion	O
,	O
the	O
NF	O
-	O
kappaB	O
inhibitor	O
and	O
antioxidant	O
PDTC	B-Chemical
protected	O
the	O
piriform	O
cortex	O
,	O
whereas	O
it	O
did	O
not	O
affect	O
hilar	O
neuronal	B-Disease
loss	I-Disease
.	O

L	B-Chemical
-	I-Chemical
NAME	I-Chemical
reduced	O
gentamicin	B-Chemical
-	O
induced	O
hearing	B-Disease
loss	I-Disease
in	O
the	O
high	O
-	O
frequency	O
range	O
,	O
but	O
gave	O
no	O
protection	O
in	O
the	O
middle	O
or	O
low	O
frequencies	O
.	O

Attenuation	O
of	O
methamphetamine	B-Chemical
-	O
induced	O
nigrostriatal	O
dopaminergic	O
neurotoxicity	B-Disease
in	O
mice	O
by	O
lipopolysaccharide	B-Chemical
pretreatment	O
.	O

Centrally	O
acting	O
alpha	O
-	O
2	O
adrenergic	O
agonists	O
are	O
one	O
of	O
several	O
pharmacologic	O
agents	O
used	O
in	O
the	O
treatment	O
of	O
spasticity	B-Disease
related	O
to	O
disorders	B-Disease
of	I-Disease
the	I-Disease
central	I-Disease
nervous	I-Disease
system	I-Disease
.	O

